Nicotine Pouches and Cardiovascular Effects: What the 2026 Evidence Shows

Nicotine pouches are sold and discussed as a harm-reduction alternative to smoking and vaping — and on respiratory measures, they are. They remove combustion, aerosol inhalation, tar, and the upper-airway exposure that drives most lung pathology in smokers and vapers. What they do not remove is nicotine, and nicotine is itself a cardiovascular toxin. Two major 2026 policy statements — from the European Heart Journal and the American Heart Association — pushed the cardiovascular conversation about pouches into the foreground for the first time. This explainer covers what the new evidence actually says, the mechanisms behind nicotine’s cardiovascular effects, how pouches compare to other formats, and what it means for users actually trying to make a decision.

For broader context on the nicotine itself, our what nicotine does explainer covers the underlying pharmacology. For specific cardiovascular symptom guides, our heart palpitations after quitting vaping and panic attacks after quitting vaping explainers cover the acute symptoms many users experience.

The 2026 European Heart Journal Statement

In April 2026, the European Heart Journal published a policy paper titled “Nicotine and the cardiovascular system: unmasking a global public health threat” (Münzel, Crea, Rajagopalan, & Lüscher, EHJ, 2026). The paper’s central conclusion: nicotine itself, independent of combustion products, is a meaningful cardiovascular toxin, and the rapid global expansion of e-cigarettes, heated tobacco, and synthetic nicotine pouches is creating a cardiovascular health threat that the public health establishment has been slow to recognize.

The paper documents that all nicotine delivery methods — cigarettes, vapes, heated tobacco, shisha, and oral nicotine pouches — consistently increase blood pressure, damage blood vessels, and elevate risk of cardiovascular disease. The damage occurs through nicotine’s direct effects on vascular endothelium and sympathetic nervous system activity, not through combustion-specific compounds. This is the cleanest scientific articulation to date of the position that pouches are not a free lunch on cardiovascular grounds.

The European Society of Cardiology issued a parallel press release describing nicotine in all forms as “toxic to the heart and blood vessels,” and explicitly including pouches in the category of products warranting public health concern (ESC, 2026).

The 2026 American Heart Association Policy Statement

Within months, the American Heart Association published its own policy statement in Circulation titled “Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment” (Circulation, 2026). The AHA statement focused specifically on smokeless oral nicotine — meaning pouches and similar formats — and reached substantially the same conclusion: pouches are not a benign category, and their cardiovascular profile deserves the same scrutiny applied to cigarettes and e-cigarettes.

The AHA statement is particularly significant because the AHA has historically been cautious about overstating risks of harm-reduction products. The 2026 statement does not equate pouches to cigarettes — it explicitly notes the absence of combustion as a meaningful difference — but it argues against the prevailing public-marketing framing of pouches as “safe” or “harmless.” The statement called for clearer labeling, restrictions on youth marketing, and clinical guidance that incorporates cardiovascular risk into pouch use recommendations.

The Mechanisms: How Nicotine Affects the Cardiovascular System

Nicotine’s cardiovascular effects operate through four documented mechanisms.

Sympathetic nervous system activation. Nicotine binds to nicotinic receptors throughout the autonomic nervous system, including those that drive sympathetic (“fight or flight”) output. The result is an immediate increase in heart rate (typically 7-15 beats per minute), systemic blood pressure (typically 5-10 mmHg systolic), and circulating catecholamines (adrenaline and noradrenaline) (Benowitz, NEJM, 2010, updated in subsequent reviews).

Endothelial dysfunction. The endothelium is the single-cell-thick lining of all blood vessels, and its function is critical for vascular health. Nicotine exposure — including from pouches — impairs endothelial function measurably within minutes of administration and chronically with sustained use. Impaired endothelial function is one of the earliest detectable events in atherosclerosis (Münzel et al., EHJ, 2026).

Peripheral vasoconstriction. Nicotine causes peripheral blood vessels to narrow, increasing vascular resistance and contributing to elevated blood pressure. The effect is detectable within minutes of pouch use and persists for hours.

Platelet activation. Nicotine promotes platelet aggregation, modestly increasing the tendency for clots to form. This is one mechanism by which cigarette smokers have elevated stroke and heart attack risk, and the same effect — at smaller magnitude — has been documented with pouch use (Circulation, 2026).

The combined effect, over years of sustained use, is a measurable contribution to atherosclerosis, hypertension, and cardiovascular event risk — independent of combustion. The magnitude is smaller than for cigarettes but is not zero.

How Pouches Compare to Cigarettes and Vapes

The cardiovascular picture is not a binary “safe vs. dangerous” sort. It’s a ranking.

Cigarettes are the highest cardiovascular risk per unit of nicotine delivered because combustion produces tar, carbon monoxide, oxidative stress, and inflammatory mediators that compound nicotine’s vascular effects. Quitting cigarettes drops cardiovascular event risk substantially within 1-2 years.

E-cigarettes (vapes) remove combustion but add heated propylene glycol and vegetable glycerin aerosol, flavoring chemicals, and (for some products) heavy metals from heating coils. Cardiovascular risk is meaningfully lower than cigarettes but not zero, and some specific products and flavor categories carry elevated risk.

Nicotine pouches remove both combustion and aerosol, leaving nicotine plus the pouch matrix (cellulose, flavoring, pH adjusters). Cardiovascular risk per nicotine dose is the lowest of the three categories — but still not zero.

Nicotine replacement therapy (medicinal NRT) — gum, patches, lozenges, inhalers — uses pharmaceutical-grade nicotine in formats designed for cessation. Cardiovascular impact is similar to pouches at equivalent dose, but NRT is FDA-approved as a medicine and is intended for short-term use with a taper plan. Our NRT guide covers the full category.

For users using pouches as a switching tool off cigarettes or vapes, the cardiovascular benefit of switching is real — substantial in most cases. For users using pouches as a nicotine source they didn’t have before, the cardiovascular cost is real even though smaller than cigarettes would be.

What the Swedish Cohort Data Show

One of the cleaner real-world data points comes from a 2025 Swedish cohort study published in Harm Reduction Journal (Harm Reduction Journal, 2025). The study tracked cardiovascular and metabolic markers in users who quit both tobacco smoking and nicotine pouches over 12 weeks. Results showed measurable improvement across the cohort after cessation — including improvements in users who had been on pouches but not on cigarettes. The study is important because it documented that pouch use, alone, has measurable cardiovascular impact reversible with cessation.

This is consistent with the policy statements above and informs the broader takeaway: pouches are not cardiovascularly neutral, and the cardiovascular benefit of pouch use is realized at cessation, not at switching.

The Magnitude of Risk for Pouch-Only Users

How worried should an actual pouch user be? Honest answer: less than a smoker, more than a non-user, and the magnitude depends heavily on dose and duration.

A few user-relevant figures:

• Resting heart rate increase from regular pouch use: typically 3-7 bpm
• Systolic blood pressure increase: typically 3-6 mmHg in chronic users
• Endothelial function impairment: detectable in lab measures, magnitude smaller than smokers’
• Long-term cardiovascular event risk: data are still maturing; expected to be elevated relative to non-users but lower than for smokers

For users with existing cardiovascular conditions — hypertension, prior heart attack, peripheral artery disease — the calculus tightens substantially. Pouches add measurable cardiovascular load on top of existing pathology. Cessation rather than long-term substitution is the better target.

For young, otherwise healthy users — particularly the 14-24 demographic where pouch use has grown most rapidly — the long-term risk of starting nicotine via pouches is meaningful, even though they avoid the worst of cigarettes’ damage. Our FDA enforcement discretion guide covers the regulatory dimension of youth-targeted pouch marketing.

What This Means for Your Strategy

A few framings that the evidence supports.

If you’re a current smoker or vaper switching to pouches: The cardiovascular case for the switch is real and supported by clinical evidence. Pouches are meaningfully better than cigarettes on cardiovascular grounds, and modestly better than vapes. Make the switch with a plan to taper down and eventually quit. Our best nicotine pouches to quit smoking and best nicotine pouches to quit vaping guides cover the switching playbook.

If you started pouches without a prior smoking or vaping habit: The cardiovascular case for continuing is weaker. The data support eventual cessation as the cardiovascular-optimal outcome. Our how to quit nicotine pouches cold turkey, nicotine pouch tapering protocol, and how to quit zyn guides cover the exit strategies.

If you have existing cardiovascular conditions: Talk to your cardiologist about your pouch use. The added load is small in absolute terms but may matter clinically. For users tapering off pouches, our quit nicotine pouches with patches and quit nicotine pouches with gum guides cover the bridge protocols.

If you’re trying to optimize the cardiovascular profile of pouch use: Lower strengths produce less cardiovascular load per dose; tobacco-flavored pouches don’t add the flavoring chemicals that some flavored pouches do; and avoiding the very high strengths (12+ mg) covered in our strongest nicotine pouches guide reduces unnecessary load. Our low-strength nicotine pouches and best tobacco-flavor nicotine pouches guides cover the gentler options.

What’s Likely to Change Next

The 2026 policy statements are likely the start of a regulatory and clinical conversation that will play out over the next 2-3 years. Expect: stronger warning labels on pouches in Europe and likely in some U.S. states; integration of pouch use into cardiovascular risk-screening tools used in primary care; and renewed scrutiny of pouch marketing language that implies cardiovascular safety. The FDA’s May 22 enforcement discretion shift and continued state-level flavor bans will determine how the U.S. retail market evolves in parallel.

Bottom Line

The 2026 EHJ and AHA policy statements settle a question that had been ambiguous: nicotine pouches have real cardiovascular effects, smaller than cigarettes but not zero, and the cardiovascular benefit of pouch use is realized at cessation rather than at switching. For switchers off cigarettes or vapes, pouches remain a better cardiovascular bet than the alternatives. For users without prior nicotine exposure, the data support cessation as the optimal target. The pharmacology is unambiguous: nicotine itself, in any delivery format, is a cardiovascular toxin.

The cardiovascular evidence is one piece of the broader pouch-safety picture. Our nicotine pouches and oral cancer research covers the 2026 Frontiers systematic review on oral cancer risk — what the evidence shows, what’s still unknown, and how to weigh the data.

For users transitioning off vaping toward cessation, the blood pressure recovery timeline is one of the earliest measurable benefits — and one of the most affected by ongoing pouch use. Our blood pressure recovery after quitting vaping guide covers how NRT and pouch use specifically interact with the recovery timeline.

The vascular pathway covered above also drives nicotine’s effects on the male endocrine system — erectile function and sperm quality are both vascularly mediated in part. Our nicotine and testosterone explainer covers the broader male-hormone picture, including the SHBG mechanism that explains why the popular nicotine-raises-T framing is misleading.

For the related cardiovascular-and-thermoregulation question of how nicotine affects skin blood flow, sweat response, and heat tolerance, our nicotine and sweat: thermoregulation guide covers the autonomic pathways.

The vasoconstrictive effects of nicotine that drive cardiovascular risk also affect bone tissue through reduced blood supply and direct osteoblast inhibition — our nicotine and bone density guide covers the parallel skeletal effects and what the 2026 evidence shows for pouches and vape users specifically.

Are nicotine pouches bad for your heart?

Yes, to a measurable degree. The 2026 American Heart Association and European Heart Journal policy statements both concluded that nicotine pouches have meaningful cardiovascular effects — including increased blood pressure, impaired endothelial function, and platelet activation — though the magnitude is smaller than for cigarettes.

Do nicotine pouches raise blood pressure?

Yes. Acute use produces an immediate 5-10 mmHg increase in systolic blood pressure, and chronic users typically show a 3-6 mmHg sustained elevation. The effect is dose-dependent — higher-strength pouches produce larger increases.

Are nicotine pouches safer for the heart than vaping?

Modestly safer per dose of nicotine, because pouches remove the heated aerosol and flavoring chemicals that contribute to vape-related cardiovascular load. Neither category is cardiovascularly neutral.

How long does it take for cardiovascular function to recover after quitting pouches?

Measurable improvements appear within 12 weeks of cessation per the 2025 Swedish cohort data. Full normalization of cardiovascular risk markers takes longer — typically 1-2 years for full recovery in users with significant prior exposure.

Should I quit nicotine pouches if I have high blood pressure?

Probably yes, and discuss with your cardiologist. The 3-6 mmHg sustained blood pressure increase from chronic pouch use compounds existing hypertension. Cessation rather than long-term substitution is the cardiovascular-optimal target for users with existing cardiovascular disease.